Stay updated on Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial
Sign up to get notified when there's something new on the Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial page.

Latest updates to the Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial page
- Check2 days agoChange DetectedThe clinical trial record for the Phase 3 Fovista and Lucentis study in age-related macular degeneration is now displayed instead of an error page. It includes the study design and results information, participant criteria, and a plan stating that individual participant data will not be shared.SummaryDifference77%

- Check9 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check16 days agoChange DetectedA banner announces NIH website transition updates and says some content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%

- Check23 days agoChange DetectedThe footer site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check30 days agoChange DetectedThe footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error page, replacing the study record details; the additions include the 403 text and header while the existing content about the trial is not accessible.SummaryDifference16%

Stay in the know with updates to Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial page.